Medindia

X

War Against Chronic Pain: Delta International Services & Logistics Starts the "GSA ready" Program in the U.S. to Provide Scrambler TherapyŽ to US Military Hospitals

Monday, May 9, 2016 Hospital News J E 4
Advertisement

ROME, May 9, 2016 /PRNewswire/ --

"Pain and opioids in the military: we must do better. In the documentary movie Escape Fire, a battle-weary and combat-wounded soldier falls out of his bunk during a medical evacuation flight from Afghanistan to Washington, DC. Disoriented from an overdose of opioid and psychoactive medications previously prescribed for his wounds, pain, and loss, he later embarks on a journey of self-healing in an effort to get off of the drugs. Unfortunately, he is not alone. In a study by Toblin et al of one of the Army's leading units published in this issue of JAMA Internal Medicine, 44.0% of the soldiers had chronic pain, and 15.1% regularly used opioids. Even accounting for the ready availability of military care, these rates are much higher than the estimates of 26.0% and 4.0%, respectively, in the general civilian population. While chronic pain and opioid use have been a long-standing concern of the military leadership, this study is among the first to quantify the impact of recent wars on the prevalence of pain and narcotic use among soldiers. The nation's defense rests on the comprehensive fitness of its service members-mind, body, and spirit. Chronic pain and use of opioids carry the risk of functional impairment of America's fighting force. (Source: Jonas WB, Schoomaker EB. Pain and opioids in the military: we must do better. JAMA Intern Med. 2014.Aug;174(8):1402-3.)"

The "GSA ready" Program 

This brief scientific article abstract is a meaningful summary of the impact of chronic pain on the military sector. Scrambler TherapyŽ was developed in Italy for the treatment of chronic neuropathic and oncologic pain resistant to opiates and other types of treatment. We think Scrambler TherapyŽ is one of the most effective possible solutions in fighting this problem. To favor its use in military hospitals, Delta International Services & Logistics has started a collaboration program with US distributors already included in the military supply system.

Value added  

Delta International Services & Logistics in this collaboration plan will provide "GSA Ready" distributors and military doctors with all necessary tools for an optimized use of this therapy, such as ST-NET support, basic and advanced training courses in Italy for trainers, and clinical trial support. Apart from Scrambler TherapyŽ hospital devices, in the mid term future we plan to develop custom devices to use in critical scenarios.

About Delta International Service & Logistics  

DIS&L is an agency created for the international development of Scrambler TherapyŽ, and selecting of medical device distributors in all international area. DIS&L through its law firm is the only company authorized to sign international exclusive agreements, provide maintenance and distributor support for method usage training and other logistics needs. For more information visit http://www.st-team.eu/news.htm.

About Scrambler TherapyŽ  

Scrambler TherapyŽ scientific research and development technology have been developed in Italy by the Italian researcher Prof. Giuseppe Marineo, the inventor of this therapy and ST technology of these devices who is the sole owner of its intellectual property rights. The official "Scrambler Therapy"Ž scientific and clinical information website is at http://www.scramblertherapy.org/english.htm). FDA 510(k) Clearance: # K142666, CE Certified:  #CE 0476)

About GEOMC Co., LTD  

GEOMC Co., LTD is the exclusive licensed manufacturer of the patent-protected Scrambler TherapyŽ for Delta International Services & Logistics.

Contact: Mariella Giorgieri: ibd@st-team.eu, +39-3921603399

SOURCE Delta International Services & Logistics

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
GenomeDx's Decipher Platform Identifies Gene Expre...
S
The Lancet Oncology publishes head-to-head study c...